Vice President, Strategic Finance and FP&A at Schrödinger

New York, New York, United States

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Pharmaceuticals, Drug Discovery, Materials ScienceIndustries

Requirements

MBA in Finance or Accounting (CPA/CFA a plus, but not required)
At least fifteen years of related public company experience
Extensive background in pharma/biotech, drug discovery, development and/or commercialization, or enterprise software
At least five years in a leadership position for FP&A or a related function
Effective communicator comfortable working with all members of the organization, including the executive leadership team and Board
Strategic thinker who can synthesize complex data and analyses into cohesive and accessible themes
Resourceful and creative problem-solver who anticipates business needs
Businessperson that understands the intersection of financial and business goals and has sound business and ethical judgement

Responsibilities

Collaborate with key executives across the organization to shape and support strategic and financial planning efforts, including development of annual and long-range plans and forecasts to support strategic decisions, as well as communications with investors
Lead Schrödinger’s financial planning, analysis and evaluation activities, including revenue and expense forecasting, cash runway analysis, and evaluation of company profitability
Oversee and develop a group of finance professionals
Build the company’s financial evaluation and analysis capabilities to support critical business development and internal investment decisions
Present the company’s financial outlook to the Board regularly
Partner with divisional leads to support planning, resourcing, and strategic execution across all areas of the company
Lead the effort to model and forecast our drug discovery portfolio through clinical stages, partnering, and potential commercialization, as well as a growing software business with significant revenue

Skills

FP&A

Strategic Finance

Financial Planning

Financial Forecasting

Revenue Forecasting

Expense Forecasting

Cash Runway Analysis

Financial Modeling

Board Presentations

Team Leadership

Investor Relations

Strategic Planning

Schrödinger

Computational platform for biopharmaceutical research

About Schrödinger

Schrödinger provides a computational platform that aids in the research efforts of biopharmaceutical companies, academic institutions, and government laboratories around the world. Their platform offers advanced computational tools that help in drug discovery and development across various therapeutic areas. Schrödinger's products work by using sophisticated algorithms and simulations to predict how different compounds will interact, which can significantly speed up the research process. Unlike many competitors, Schrödinger not only licenses its software but also engages in collaborative research and drug discovery programs, allowing for a more integrated approach to scientific research. The company's goal is to enhance scientific research and development through its platform, ultimately leading to the discovery of new drugs and therapies.

New York City, New YorkHeadquarters

1990Year Founded

$362.7MTotal Funding

IPOCompany Stage

Government & Public Sector, Enterprise Software, BiotechnologyIndustries

501-1,000Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

401(k) Retirement Plan

Flexible Work Hours

Remote Work Options

Paid Vacation

Parental Leave

Risks

Recursion and Exscientia merger creates strong AI-driven drug discovery competitor.

Avicenna's independent expansion could lead to competitive tensions with Schrödinger.

High R&D costs may strain resources despite Gates Foundation's $10M grant.

Differentiation

Schrödinger's platform supports diverse clients, including biopharma, academia, and government labs.

The company excels in rapid drug discovery, exemplified by SGR-1505's swift development.

Schrödinger's collaboration with Avicenna enhances medicinal chemistry through machine learning.

Upsides

$19.5M Gates Foundation grant boosts platform for neglected diseases, expanding market reach.

Predictive toxicology tools initiative could lead to safer, efficient drug development.

SGR-1505 discovery showcases ability to reduce drug discovery timelines significantly.

Land your dream remote job 3x faster with AI

Try Jobo Free